13 results about "Ondansetron" patented technology

The invention provides an ondansetron water-free swallowing granule which comprises an ondansetron granule and a flavoring granule, the ondansetron granule sequentially comprises a pill core, a drug-containing layer, an isolating layer and a smooth layer from inside to outside, and the ondansetron granule and the flavoring granule are mixed and filled in a two-channel filling mode. The ondansetron water-free swallowing granules are beneficial to rapid swallowing in the oral cavity, good taste of the preparation is ensured in the whole process, the technical characteristics of water-free swallowing are realized, the taking compliance of a patient is improved, the stability of the raw material medicines is also improved, the problem of ondansetron degradation of ondansetron or a salt preparation thereof is solved, and the ondansetron water-free swallowing granules are suitable for being used in oral administration. The growth of related substances is effectively reduced, and the stability and safety of the preparation are ensured.

1. The name of the design product: packaging box (ondansetron mouth dissolving film). 2. The use of the design product: for the packaging of medicines. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view.

The present invention relates to a controlled release injectable ondansetron formulation comprising ondansetron or pharmaceutically acceptable salt, derivative or metabolite thereof which releases ondansetron over a period of at least 2 days period from the date of administration and the process for preparation thereof.

The present invention relates to a controlled release injectable ondansetron formulation comprising ondansetron or pharmaceutically acceptable salt, derivative or metabolite thereof which releases ondansetron over a period of at least 2 days period from the date of administration and the process for preparation thereof.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The invention relates to the technical field of biological medicine, in particular to a medicine solution composition, a preparation method thereof, a nasal spray and application. The medicine solution composition comprises a medicine active component, an osmotic pressure regulator, a pH regulator and water. The active pharmaceutical ingredient comprises ondansetron or a pharmaceutically acceptable salt of ondansetron. The medicine solution composition provided by the invention can be quickly absorbed into blood through nasal mucosa, reaches a peak within 5-10 minutes after being administered through nasal spray administration, is expected to take effect quickly, can help a patient to deal with nausea and vomiting caused by cytotoxic chemotherapy and radiotherapy in time and be used for preventing postoperative nausea and vomiting (PONV), and is good in stability.

This invention provides a safer drug and its application, and a safer drug combination and its application without sudden cardiac death toxicity. The safer drug provided by this invention is a combination preparation containing a serotonin receptor antagonist and diltiazem, which effectively avoids the possibility of ventricular depolarization and repolarization disorders caused by the serotonin receptor antagonist ondansetron, thereby preventing corresponding arrhythmias and sudden cardiac death. This application also provides the application of diltiazem in the preparation of drugs that improve cardiac electrical activity and corresponding treatment methods.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The invention relates to a formula and a preparation process of an ondansetron oral soluble film, the ondansetron oral soluble film comprises the following components: ondansetron, a water-soluble film-forming polymer, a combination of starch A and starch B, a plasticizer and a surfactant, two or more starch types are preferably selected, and the ondansetron oral soluble film is prepared by matching the ondansetron with the water-soluble film-forming polymer. The prepared oral soluble film solves the problems of curling after film formation and drying and oil discharge during storage, and further improves the tensile strength and rapid disintegration of the film agent.

Provided are a safer drug and the use thereof. Provided are a pharmaceutical composition which is safer and which does not have toxicity leading to sudden cardiac death, and the use thereof. The provided safer drug is a compound formulation containing a 5-hydroxytryptamine receptor antagonist and diltiazem, and can effectively avoid the possibility of cardiac arrhythmia and sudden cardiac death due to ventricular depolarization and repolarization disorders caused by the 5-hydroxytryptamine receptor antagonist ondansetron. Further provided are the use of diltiazem in preparing a drug for improving electrical activity of the heart and a corresponding therapeutic method.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The disclosure relates to the field of alcohol use disorder. The disclosure provides methods of treating a subject having alcohol use disorder that includes administering ondansetron to a subject having a specified genotype corresponding to genetic variants that effect the 5-HT3 receptor complexes to which ondansetron binds and / or genetic variants that effect the expression of the serotonin transporter.